FDA Approval and Growth Acceleration Impress!
BLA approval for Avance is a milestone in commercialization
The addressable US market potential is $5.6 billion
Reading Time: 1 minute
AxoGen (AXGN) is one of my top breakout candidates among the medical technology stocks. The company provides specialized products for the treatment of peripheral nerve injuries. A milestone is the BLA approval from the FDA on December 3 for the core product Avance Nerve Graft, which will be commercially available as an allogenic human nerve transplant starting in the second quarter of 2026. The approval is expected to increase physician acceptance, and the gap of 35% of commercially insured patients in the US that remains uncovered is set to close...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
